Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes

Table 2 Multiple logistic regression models for associations between clinical and biochemical variables and the progression of diabetic nephropathy in a total of 154 subjects with T1D

	Model 1			Model 2			Model 3
	(R ² = 0.28)			(R ² = 0.20)			(R ² = 0.28)
Variables	OR	95 % CI	P	OR	95 % CI	P	OR	95 % CI	P
Age, per year	1.03	0.99–1.07	0.132	1.03	0.99–1.06	0.188	1.03	0.99–1.07	0.136
Obesity (0 = no, 1 = yes)	1.92	0.64–5.78	0.243	1.95	0.69–5.55	0.210	1.94	0.64–5.81	0.242
Duration of diabetes, per 5years	1.44	1.01–2.07	0.047	1.28	0.92–1.77	0.145	1.44	1.01–2.07	0.047
Hypertension (0 = no, 1 = yes)	2.32	0.77–6.99	0.134	2.09	0.79–5.83	0.160	2.32	0.77–6.98	0.136
Albuminuria at baseline (0 = no, 1 = yes)	2.63	1.03–6.73	0.043	2.86	1.16–7.07	0.023	2.64	1.03–6.74	0.043
Statin use (0 = no, 1 = yes)	1.89	0.74–4.88	0.186	1.49	0.59–3.75	0.403	1.91	0.73–5.01	0.188
CKD stage at baseline
Stage1	Reference			Reference			Reference
Stage2	0.55	0.16–1.86	0.338	0.71	0.23–2.24	0.559	0.55	0.16–1.86	0.337
Stage3 and 4	0.09	0.01–1.30	0.078	0.12	0.01–1.54	0.103	0.09	0.01–1.31	0.078
mean GA (%)*	2.02	1.28–3.17	0.002				2.03	1.27–3.26	0.003
mean HbA_1c (%)*				1.21	0.79–1.85	0.390	0.98	0.62–1.54	0.918

ISSN: 1475-2840